Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).

Locations

16 United States sites

3 Canada sites

Age

18 Years - 50 Years

Phase

Phase 1/Phase 2

LEARN MORE
Building Adaptive Coping and Knowledge to Improve Daily Life (Back2Life): A Pilot Feasibility Clinical Trial for Youth With Chronic Sickle Cell Pain

The purpose of this study is to find out how teenagers with chronic pain and sickle cell disease respond to a new training program called Back2Life and get their feedback about how to modify the program to best fit their needs.

Locations

3 United States sites

Age

10 Years - 18 Years

Phase

Not Applicable

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

49 United States sites

5 France sites

5 Spain sites

4 Greece sites

4 Italy sites

4 United Kingdom sites

3 Canada sites

2 Lebanon sites

2 Germany sites

Age

12 Years - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
Kinetics of Donor Red Blood Cell Survival in Sickle Cell Disease

This is a single-arm, mechanistic clinical trial to measure predictors of senescence and the in vivo survival of transfused red blood cells (RBCs) in individuals with sickle cell disease (SCD) receiving chronic transfusion therapy (CTT).

Locations

3 United States sites

Age

> 6 Years

Genotypes

HbSS

Phase

Phase 1

LEARN MORE
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant (ASCENT)

The ASCENT Trial is a single arm, multi-center, phase II study.

Locations

9 United States sites

Age

< 20 Years

Phase

Phase 2

LEARN MORE
Sickle Cell Disease and CardiovAscular Risk – Red Cell Exchange Trial (SCD-CARRE)

The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.

Locations

18 United States sites

1 United Kingdom site

1 France site

Age

> 18 Years

Phase

Phase 3

LEARN MORE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease

This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.

Locations

17 United States sites

5 Nigeria sites

4 Egypt sites

4 Kenya sites

4 United Kingdom sites

3 Italy sites

2 Ghana sites

2 Oman sites

2 Saudi Arabia sites

1 France site

Age

2 Years - 14 Years

Genotypes

SCA

Phase

Phase 3

LEARN MORE
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)

The goal of the study is to evaluate the efficacy and safety of crizanlizumab in SCD patients with priapism.

Locations

19 United States sites

Age

> 16 Years

Genotypes

HbSS, HbSC

Phase

Phase 2

LEARN MORE
Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Advocacy and Research Alliance (STAR) Trial

This study aims to enroll 58 pre-adolescent (<13 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor.

Locations

11 United States sites

Age

2 Years - 13 Years

Genotypes

HbSS

Phase

Phase 2

LEARN MORE
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD).

Locations

6 United States sites

Age

18 Years - 40 Years

Genotypes

HbSS

Phase

Phase 1/Phase 2

LEARN MORE